Showing results (71-80 of 210) with videos related to

Sort By:
Pageof 21
Prostaglandins & Other Lipid Mediators|April 10, 2024
A high seizure burden increases several prostaglandin species in the hippocampus of a Scn1a<sup>+/-</sup> mouse model of Dravet syndromeCilla Zhou, Vaishali Satpute, Ka Lai Yip, et al.
Frontiers in Pharmacology|June 3, 2021
The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the <i>Scn1a</i> <sup></sup> Mouse Model of Dravet SyndromeVaishali Satpute Janve, Lyndsey L Anderson, Dilara Bahceci, et al.
Basic & Clinical Pharmacology & Toxicology|December 26, 2024
Preclinical Evidence for a Drug-Drug Interaction Between Cannabinol and MelatoninLyndsey L Anderson, Nicole A Hawkins, Ka Lai Yip, et al.
Prostaglandins & Other Lipid Mediators|December 19, 2024
A high seizure burden increases brain concentrations of specialized pro-resolving mediators in the Scn1a<sup>+/-</sup> mouse model of Dravet syndromeKa Lai Yip, Cilla Zhou, Lyndsey L Anderson, et al.
Plos One|February 2, 2016
Cerebral Apolipoprotein-D Is Hypoglycosylated Compared to Peripheral Tissues and Is Variably Expressed in Mouse and Human Brain RegionsHongyun Li, Kalani Ruberu, Tim Karl, et al.
Genes, Brain, and Behavior|April 19, 2021
Behavioural effects of cage systems on the G93A Superoxide Dismutase 1 transgenic mouse model for amyotrophic lateral sclerosisStefan Guerra, Roger Chung, Justin Yerbury, et al.
Behavioural Brain Research|October 6, 2005
Effect of Y1 receptor deficiency on motor activity, exploration, and anxietyTim Karl, Thomas H J Burne, Herbert Herzog
Behavioural Brain Research|November 3, 2009
Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiencyTim Karl, Rose Chesworth, Liesl Duffy, et al.
Frontiers in Pharmacology|January 11, 2021
Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of <i>APP</i> <sub></sub> <i>/PS1ΔE9</i> Transgenic Female MiceMadilyn Coles, Georgia Watt, Fabian Kreilaus, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 25, 2026
Cannabidiol (CBD) does not reduce cocaine reward or self-administration in a mouse model of schizophrenia genetic susceptibilityRose Chesworth, Georgia Watt, Erin McLemon, et al.
Pageof 21